|
WO2021077013A1
|
|
Combination therapy for treatment of cancers
|
|
WO2021041912A1
|
|
Reactivating p53 mutants for cancer treatment by targeting prolidase (pepd)
|
|
WO2021021741A1
|
|
Treatment of p53-deficient cancers
|
|
WO2020223174A1
|
|
Coumarin-modified androgens for the treatment of prostate cancer
|
|
WO2020198361A1
|
|
Tetrapyrrolic conjugates and uses thereof for imaging
|
|
WO2020185977A1
|
|
Medicinal nebulizer and method of dispensing medicament
|
|
WO2020168185A1
|
|
In vivo magnetic resonance image distortion check apparatus and method
|
|
WO2020160450A1
|
|
Methods and compositions for treating resistant and recurrent forms of cancer
|
|
WO2020097317A1
|
|
Exploiting estrogen receptor beta and tp53 interaction as a new therapeutic strategy for cancer
|
|
WO2020092656A1
|
|
Devices and methods for automatic suture
|
|
WO2020092344A1
|
|
Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
|
|
WO2020092382A1
|
|
Cancer specific immunotherapeutic targets generated by chemotherapeutic drug treatment
|
|
CA3109176A1
|
|
Compositions and methods related to overcoming innate immune barriers to cancer immunotherapy
|
|
US2019352644A1
|
|
Inhibition of mitochondrial hypoxic stress induced rna editing by apobec3g cytidine deaminase
|
|
CA3106980A1
|
|
Major histocompatibility complex class ll-expressing cancer cell vaccine and methods of use for producing integrated immune responses
|
|
US2021008305A1
|
|
Induction spacer for inhaler
|
|
US2019201516A1
|
|
Composition and method for generating immunity to Borrelia burgdorferi
|
|
WO2019090244A2
|
|
Myeloid-derived suppressor cell cluster analysis in vitro
|
|
US2020281778A1
|
|
Incontinence device
|
|
CA3075419A1
|
|
Tetrapyrrolic conjugates and uses thereof for imaging
|
